Ivosidenib in relapsed or refractory acute myeloid leukemia: a profile of its use in the USA (vol 35, pg 160, 2019)

被引：0
|
作者：
McCafferty, Emma H. [1 ]
Lyseng-Williamson, Katherine Ann [1 ]
机构：
[1] Springer, Private Bag 65901,Mairangi Bay, Auckland 0754, New Zealand
来源：
DRUGS & THERAPY PERSPECTIVES | 2019年 / 35卷 / 09期
关键词：
D O I：
10.1007/s40267-019-00645-5
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The original article has been corrected.
引用
收藏
页码：460 / 460
页数：1
相关论文
共 50 条
  • [21] Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation
    Ballesta-Lopez, Octavio
    Solana-Altabella, Antonio
    Megias-Vericat, Juan Eduardo
    Martinez-Cuadron, David
    Montesinos, Pau
    FUTURE ONCOLOGY, 2020, 17 (02) : 215 - 228
  • [22] Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid Leukemia (vol 143, pg 438, 2020)
    Westhus
    ACTA HAEMATOLOGICA, 2021, 144 (02) : 236 - 236
  • [23] Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use (vol 35, pg 470, 2019)
    Deeks, Emma
    DRUGS & THERAPY PERSPECTIVES, 2019, 35 (12) : 635 - 635
  • [24] Clinico-hematological profile in biphenotypic acute leukemia (vol 46, pg 160, 2009)
    Gujral, S.
    Polampalli, S.
    Badrinath, Y.
    Kumar, A.
    Chogule, A.
    Subramanian, P. G.
    Raje, G.
    Amare, P.
    Arora, B.
    Banavali, S. D.
    Nair, C. N.
    INDIAN JOURNAL OF CANCER, 2010, 47 (01) : 30 - 30
  • [25] Implementation of Inpatient Palliative Care Consultation Triggers and Its Impact on Healthcare Use in Patients with Relapsed/Refractory Acute Myeloid Leukemia
    Xiang, Jenny J.
    Prsic, Elizabeth Horn
    Adelson, Kerin B.
    Prebet, Thomas
    BLOOD, 2021, 138
  • [26] The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia
    Marconi, Giovanni
    Giannini, Maria Benedetta
    Bagnato, Gianmarco
    Simonetti, Giorgia
    Cerchione, Claudio
    Mosquera Orgueira, Adrian
    Musuraca, Gerardo
    Martinelli, Giovanni
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (07) : 791 - 799
  • [27] Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant
    DiNardo, Courtney D.
    Stein, Eytan M.
    Pigneux, Arnaud
    Altman, Jessica K.
    Collins, Robert
    Erba, Harry P.
    Watts, Justin M.
    Uy, Geoffrey L.
    Winkler, Thomas
    Wang, Hongfang
    Choe, Sung
    Liu, Hua
    Wu, Bin
    Kapsalis, Stephanie M.
    Roboz, Gail J.
    de Botton, Stephane
    LEUKEMIA, 2021, 35 (11) : 3278 - 3281
  • [28] The Use of Clofarabine and Cytarabine Combination (CLARA) As Salvage Therapy for Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
    Leung, Anskar Y. H.
    Tse, Eric
    Liu, Herman S. Y.
    Sim, Joycelyn
    Kho, Bonnie C. S.
    Yip, Sze-Fai
    Lee, Harold K. K.
    Kwong, Yok Lam
    BLOOD, 2012, 120 (21)
  • [29] Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia
    Metzelder, Stephan
    Scholl, Sebastian
    Matthias, Kroeger
    Reiter, Andreas
    Meyer, Ralf G.
    Heinicke, Thomas
    Giagounidis, Aristoteles
    Wolfgang, Brugger
    Voehringer, Mathias
    Stadler, Michael
    Schultheis, Beate
    Mueller, Lothar
    Haenel, Mathias
    Hochhaus, Andreas
    Enghofer, Erich
    Neubauer, Andreas
    Burchert, Andreas
    BLOOD, 2009, 114 (22) : 813 - 814
  • [30] Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis
    Ma, Yuan-yuan
    Zhao, Min
    Liu, Yi
    Zhao, De-feng
    Wang, Li-xin
    Chen, Xiao-ping
    Li, Li
    HEMATOLOGY, 2019, 24 (01) : 507 - 515
12345